Business
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
CAMBRIDGE, Mass., May 20, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If confi
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/cc244091aead9657bfef8979cb0a1451"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GQym.WrOIQEZtyfT822cYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cc244091aead9657bfef8979cb0a1451","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/QqJY2NOjPGjOxwmIzOwWAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/cc244091aead9657bfef8979cb0a1451","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Enveric files provisional patent application on newly identified group of molecules","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., May 20, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that it has filed a new provisional patent application with claims to methods and pharmaceutical formulations for use on a family of molecules discovered to offer potential to address neurodegenerative disease. If confirmed through further testing, the potential of this newly identified group of molecules expands the market potential for Enveric drug candidates in a new direction.","length":701,"tagName":"p"},{"type":"text","content":"Neurodegenerative diseases are a heterogenous group of progressive neurological disorders characterized by the gradual loss of neurons, leading to a decline in cognitive, motor and other neurological functions. It has been estimated by the World Health Organization (WHO) that approximately 50 million people worldwide are affected by neurodegenerative diseases, with seven million in the United States.","length":403,"tagName":"p"},{"type":"text","content":"Broad claims in the patent application describe a group of molecules that enhance brain derived neurotrophic factor ("BDNF") activity and address conditions where the BDNF/TrKB pathway plays a major role. BDNF and its receptor TrKB support neuroprot...